627 related articles for article (PubMed ID: 26996169)
1. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
2. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
4. Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals.
Amat-Ur-Rasool H; Ahmed M
PLoS One; 2015; 10(9):e0136509. PubMed ID: 26325402
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer's disease agents.
Gao H; Jiang Y; Zhan J; Sun Y
Bioorg Chem; 2021 Sep; 114():105149. PubMed ID: 34252860
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
7. Potential acetylcholinesterase inhibitors to treat Alzheimer's disease.
Saud A; Krishnaraju V; Taha A; Kalpana K; Malarkodi V; Durgaramani S; Vinoth Prabhu V; Saleh FA; Ezhilarasan S
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2522-2537. PubMed ID: 38567612
[TBL] [Abstract][Full Text] [Related]
8. Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies.
Iqbal J; Abbasi MSA; Zaib S; Afridi S; Furtmann N; Bajorath J; Langer P
Med Chem; 2018; 14(8):809-817. PubMed ID: 29473519
[TBL] [Abstract][Full Text] [Related]
9. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
Okello EJ; Mather J
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457
[TBL] [Abstract][Full Text] [Related]
10. Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Kumar A; Pintus F; Di Petrillo A; Medda R; Caria P; Matos MJ; Viña D; Pieroni E; Delogu F; Era B; Delogu GL; Fais A
Sci Rep; 2018 Mar; 8(1):4424. PubMed ID: 29535344
[TBL] [Abstract][Full Text] [Related]
11. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
12. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
14. Identification of Compounds for Butyrylcholinesterase Inhibition.
Li S; Li AJ; Travers J; Xu T; Sakamuru S; Klumpp-Thomas C; Huang R; Xia M
SLAS Discov; 2021 Dec; 26(10):1355-1364. PubMed ID: 34269114
[TBL] [Abstract][Full Text] [Related]
15. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
16. In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones.
Lee S; Youn K; Lim G; Lee J; Jun M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29932100
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines.
Basiri A; Abd Razik BM; Ezzat MO; Kia Y; Kumar RS; Almansour AI; Arumugam N; Murugaiyah V
Bioorg Chem; 2017 Dec; 75():210-216. PubMed ID: 28987876
[TBL] [Abstract][Full Text] [Related]
18. In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
Gholami A; Minai-Tehrani D; Eriksson LA
Sci Rep; 2023 Jan; 13(1):643. PubMed ID: 36635365
[TBL] [Abstract][Full Text] [Related]
19. Identification of Natural Compounds of the Apple as Inhibitors against Cholinesterase for the Treatment of Alzheimer's Disease: An In Silico Molecular Docking Simulation and ADMET Study.
Jamal QMS; Khan MI; Alharbi AH; Ahmad V; Yadav BS
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049419
[TBL] [Abstract][Full Text] [Related]
20. Quinoxaline derivatives: novel and selective butyrylcholinesterase inhibitors.
Zeb A; Hameed A; Khan L; Khan I; Dalvandi K; Choudhary MI; Basha FZ
Med Chem; 2014; 10(7):724-9. PubMed ID: 24875826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
